Aberrant splicing in Huntington's disease via disrupted TDP-43 activity accompanied by altered m6A RNA modification

• Published in: bioRxiv : the preprint server for biology
• Main Authors: Nguyen, Thai B, Miramontes, Ricardo, Chillon-Marinas, Carlos, Maimon, Roy, Vazquez-Sanchez, Sonia, Lau, Alice L, McClure, Nicolette R, England, Whitney E, Singha, Monika, Stocksdale, Jennifer T, Jang, Ki-Hong, Jung, Sunhee, McKnight, Jharrayne I, Ho, Leanne N, Faull, Richard L M, Steffan, Joan S, Reidling, Jack C, Jang, Cholsoon, Lee, Gina, Cleveland, Don W, Lagier-Tourenne, Clotilde, Spitale, Robert C, Thompson, Leslie M
• Format: Journal Article
• Language: English
• Published: United States 02.11.2023

Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the first exon of the gene encoding huntingtin. Prior reports have established a correlation between CAG expanded and altered gene expression. However, the mechanisms leading to disruption of RNA processing in HD remain unclear. Here, our analysis of the reported HTT protein interactome identifies interactions with known RNA-binding proteins (RBPs). Total, long-read sequencing and targeted RASL-seq of RNAs from cortex and striatum of the HD mouse model R6/2 reveals increased exon skipping which is confirmed in Q150 and Q175 knock-in mice and in HD human brain. We identify the RBP TDP-43 and the N6-methyladenosine (m6A) writer protein methyltransferase 3 (METTL3) to be upstream regulators of exon skipping in HD. Along with this novel mechanistic insight, we observe decreased nuclear localization of TDP-43 and cytoplasmic accumulation of phosphorylated TDP-43 in HD mice and human brain. In addition, TDP-43 co-localizes with HTT in human HD brain forming novel nuclear aggregate-like bodies distinct from mutant HTT inclusions or previously observed TDP-43 pathologies. Binding of TDP-43 onto RNAs encoding HD-associated differentially expressed and aberrantly spliced genes is decreased. Finally, m6A RNA modification is reduced on RNAs abnormally expressed in striatum from HD R6/2 mouse brain, including at clustered sites adjacent to TDP-43 binding sites. Our evidence supports TDP-43 loss of function coupled with altered m6A modification as a novel mechanism underlying alternative splicing/unannotated exon usage in HD and highlights the critical nature of TDP-43 function across multiple neurodegenerative diseases.